TY - JOUR
T1 - Translating cancer risk prediction models into personalized cancer risk assessment tools
T2 - Stumbling blocks and strategies for success
AU - Waters, Erika A.
AU - Taber, Jennifer M.
AU - McQueen, Amy
AU - Housten, Ashley J.
AU - Studts, Jamie L.
AU - Scherer, Laura D.
N1 - Funding Information:
E.A. Waters and A.J. Housten were supported by grants from the NIH (R01CA190391 to E.A. Waters; R00MD011485 to A.J. Housten).
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/12
Y1 - 2020/12
N2 - Cancer risk prediction models such as those published in Cancer Epidemiology, Biomarkers, and Prevention are a cornerstone of precision medicine and public health efforts to improve population health outcomes by tailoring preventive strategies and therapeutic treatments to the people who are most likely to benefit. However, there are several barriers to the effective translation, dissemination, and implementation of cancer risk prediction models into clinical and public health practice. In this commentary, we discuss two broad categories of barriers. Specifically, we assert that the successful use of risk-stratified cancer prevention and treatment strategies is particularly unlikely if risk prediction models are translated into risk assessment tools that (i) are difficult for the public to understand or (ii) are not structured in a way to engender the public's confidence that the results are accurate. We explain what aspects of a risk assessment tool's design and content may impede understanding and acceptance by the public. We also describe strategies for translating a cancer risk prediction model into a cancer risk assessment tool that is accessible, meaningful, and useful for the public and in clinical practice.
AB - Cancer risk prediction models such as those published in Cancer Epidemiology, Biomarkers, and Prevention are a cornerstone of precision medicine and public health efforts to improve population health outcomes by tailoring preventive strategies and therapeutic treatments to the people who are most likely to benefit. However, there are several barriers to the effective translation, dissemination, and implementation of cancer risk prediction models into clinical and public health practice. In this commentary, we discuss two broad categories of barriers. Specifically, we assert that the successful use of risk-stratified cancer prevention and treatment strategies is particularly unlikely if risk prediction models are translated into risk assessment tools that (i) are difficult for the public to understand or (ii) are not structured in a way to engender the public's confidence that the results are accurate. We explain what aspects of a risk assessment tool's design and content may impede understanding and acceptance by the public. We also describe strategies for translating a cancer risk prediction model into a cancer risk assessment tool that is accessible, meaningful, and useful for the public and in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85099945260&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-20-0861
DO - 10.1158/1055-9965.EPI-20-0861
M3 - Review article
C2 - 33046450
AN - SCOPUS:85099945260
SN - 1055-9965
VL - 29
SP - 2389
EP - 2394
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 12
ER -